OUR BUSINESS

We hold hands with our global partners and head
towards the world through CDMO / R&D.

SAMIL R&D PIPELINE

Samil Pharm’s PIPELINE focuses on eye and liver diseases, and completes 360º Human Care through the development of innovative medicines.

R&D PIPELINE As of 07.20.2022

Eye Disease
Project Name Indication Category
  • Research
  • Pre-C
  • Phase1
  • Phase2
  • Phase3
  • NDA
 Year of Release
ZVT eye drop Conjunctivitis IMD 2022
KSR-001 eye drop Dry eye IMD 2022
SIF-1002 Tab Dry eye Functional Food 2021
Liver Disease
Project Name Indication Category
  • Research
  • Pre-C
  • Phase1
  • Phase2
  • Phase3
  • NDA
 Year of Release
Aramchol Tab NASH NCE 2025
SIF-2002 Tab Fatty liver Disease Functional Food 2023
Digestive System
Project Name Indication Category
  • Research
  • Pre-C
  • Phase1
  • Phase2
  • Phase3
  • NDA
 Year of Release
SII-3001 Tab GI ulcer IMD 2025
FDC Tab GI ulcer IMD After 2027
Circulatory System Musculoskeletal
Project Name Indication Category
  • Research
  • Pre-C
  • Phase1
  • Phase2
  • Phase3
  • NDA
 Year of Release
SII-5001 Tab Pain IMD After 2023
SM04690 Knee osteoarthritis NCE 2023

ZVT eye drop

닫기
  • Developed by Nicox S.A. and received FDA approval in May 2017
    Samil Pharmaceuticals licensed-in the product in December 2019
  • The world’s first ophthalmic solution with cetirizine
  • Relieve itching in a short time

KSR-001 eye drop

닫기
  • Targeting the Japanese Mucosta® ophthalmic suspension UD 2% (Otsuka). Incrementally modified drug not infringing the patent of the composition of matter.
  • Several research results supporting that rebamipide and diquafosol have the equivalent medical effects
  • Improved comfort(stinging, bitterness) compared to the original

SIF-1002 Tab

닫기
  • The technology of Korea Institute of Oriental Medicine with R&D support of the government
  • New introduction of health supplements in the dry eye market limited to only Omega-3
  • Ingredients subject to examination which granted for functional ingredients, that allowing only Samil to process the business based on its feature and originality.

Aramchol Tab

닫기
  • Prevent accumulation of liver fat which causes NASH through suppression of SCD1 (Stearoyl-CoA desaturase 1) in liver
  • Global Phase 3 trial in progress (for 2,000 patients)
  • Aims to get the approval and registration done in the 4th quarter of 2024 and launch in the 4th quarter of 2025

SIF-2002 Tab

닫기
  • Developed individually recognized materials using Mongolian naturally extracted oil
  • Verifying the reduction of blood lipids and relief of liver disease symptoms through non-clinical tests
  • Individually recognized materials, and available for sales with the originality of Samil Pharm

SIN-2001 Tab

닫기
  • International SCI paper Nature Communications (Published on IF. 11.87.2019)
  • There are many patients with the chronic hepatitis B virus, which was not eliminated even with conventional antiviral treatment.
  • Developing a new-concept antiviral drug that shows minimal toxicity with a mechanism that inhibits the vital life cycle of the hepatitis B virus.

SII-3001 Tab

닫기
  • IMD with an improved onset time of the existing mucosal-protective agents (Protection of the gastric mucous membrane)
  • Development of the product that promotes regeneration of the gastric mucous membrane in a short period of time
  • Secured the therapeutic equivalence to the existing mucosal-protective agents through the pre-clinical test

FDC Tab

닫기
  • A fixed dose combination drug comprised of two different therapeutics (gastric acid secretion inhibitor & functional dyspepsia treatment) allowing easier dose regimen for the patients.

SII-5001

닫기
  • Developed a product that has improved patient compliance by reducing the possibility of side effects such as hot flashes and the number of administrations.
  • Developed a sustained-release agent based on our platform technology

SM04690

닫기
  • New chemical entity for knee osteoarthritis treatment licensed from Biosplice Therapeutics (U.S.A)
  • It is in development as a world’s first potential DMOAD(disease-modifying osteoarthritis drug) treatment
  • U.S. Phase 3 clinical trial ongoing (subjects approx. 1,000)
155 Hyoryeong-ro, Seocho-gu, Seoul (Samil Pharm Office Building, Bangbae-dong) +82-2-520-0300
COPYRIGHT(c) SAMIL CO. LTD. ALL RIGHTS RESERVED
R&D

SAMIL R&D PIPELINE

Samil Pharm’s PIPELINE focuses on eye and liver diseases, and completes 360º Human Care through the development of innovative medicines.

R&D PIPELINE As of 07.20.2022

Eye Disease
Project Name Indication Category Research Pre-C Phase1 Phase2 Phase3 NDA Year of Release
ZTV eye drop Conjunctivitis IMD
2022
KSR-001 eye drop Dry eye IMD
2022
SIF-1002 Tab Dry eye Functional Food
2022
Liver Disease
Project Name Indication Category Research Pre-C Phase1 Phase2 Phase3 NDA Year of Release
Aramchol Tab NASH NCE
2022
SIF-2002 Tab Fatty liver Disease Functional Food
2022
Digestive System
Project Name Indication Category Research Pre-C Phase1 Phase2 Phase3 NDA Year of Release
Sll-3001 Tab Gl ulcer IMD
2025
FDC Tab Gl ulcer IMD
After 2027
Circulatory System Musculoskeletal
Project Name Indication Category Research Pre-C Phase1 Phase2 Phase3 NDA Year of Release
Sll-5001 Tab Pain IMD
After 2023
SM04690 Knee osteoarthritis NCE
2023

ZVT eye drop

닫기
  • Developed by Nicox S.A. and received FDA approval in May 2017. Samil Pharmaceuticals licensed-in the product in December 2019
  • The world’s first ophthalmic solution with cetirizine
  • Relieve itching in a short time

KSR-001 eye drop

닫기
  • Targeting the Japanese Mucosta® ophthalmic suspension UD 2% (Otsuka). Incrementally modified drug not infringing the patent of the composition of matter.
  • Several research results supporting that rebamipide and diquafosol have the equivalent medical effects.
  • Improved comfort(stinging, bitterness) compared to the original

SIF-1002 Tab

닫기
  • The technology of Korea Institute of Oriental Medicine with R&D support of the government
  • New introduction of health supplements in the dry eye market limited to only Omega-3
  • Ingredients subject to examination which granted for functional ingredients, that allowing only Samil to process the business based on its feature and originality.

Aramchol Tab

닫기
  • Prevent accumulation of liver fat which causes NASH through suppression of SCD1 (Stearoyl-CoA desaturase 1) in liver
  • Global Phase 3 trial in progress (for 2,000 patients)
  • Aims to get the approval and registration done in the 4th quarter of 2024 and launch in the 4th quarter of 2025

SIF-2002 Tab

닫기
  • Developed individually recognized materials using Mongolian naturally extracted oil
  • Verifying the reduction of blood lipids and relief of liver disease symptoms through non-clinical tests
  • Individually recognized materials, and available for sales with the originality of Samil Pharm

SIN-2001 Tab

닫기
  • International SCI paper Nature Communications (Published on IF. 11.87.2019)
  • There are many patients with the chronic hepatitis B virus, which was not eliminated even with conventional antiviral treatment.
  • Developing a new-concept antiviral drug that shows minimal toxicity with a mechanism that inhibits the vital life cycle of the hepatitis B virus.

SII-3001 Tab

닫기
  • IMD with an improved onset time of the existing mucosal-protective agents (Protection of the gastric mucous membrane)
  • Development of the product that promotes regeneration of the gastric mucous membrane in a short period of time
  • Secured the therapeutic equivalence to the existing mucosal-protective agents through the pre-clinical test

FDC Tab

닫기
  • A fixed dose combination drug comprised of two different therapeutics (gastric acid secretion inhibitor & functional dyspepsia treatment) allowing easier dose regimen for the patients.

SII-5001 Tab

닫기
  • Developed a product that has improved patient compliance by reducing the possibility of side effects such as hot flashes and the number of administrations.
  • Developed a sustained-release agent based on our platform technology

SM04690

닫기
  • New chemical entity for knee osteoarthritis treatment licensed from Biosplice Therapeutics (U.S.A)
  • It is in development as a world’s first potential DMOAD(disease-modifying osteoarthritis drug) treatment
  • U.S. Phase 3 clinical trial ongoing (subjects approx. 1,000)
로고

155 Hyoryeong-ro, Seocho-gu, Seoul
(Samil Pharm Office Building, Bangbae-dong) +82-2-520-0300

COPYRIGHT⒞ SAMIL CO. LTD. ALL RIGHTS RESERVED